The maintenance of a Buy rating suggests continued confidence in Cyclacel Pharmaceuticals' fundamentals or growth prospects, despite the significant reduction in the price target. This could indicate a reassessment of the company's near-term revenue or profit potential, possibly due to new data or market conditions. The lowered price target might lead to short-term negative sentiment among investors, but the Buy rating could mitigate some of the negative impact.